secwatch.observer — SEC 8-K summary
======================================

Issuer:     Akari Therapeutics Plc (AKTX)
CIK:        0001541157
Form:       8-K
Filed at:   2025-12-16T23:59:59+00:00
Accession:  0001493152-25-027969
Event type: other_material
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Akari shareholders approve share sub-division, warrant exercise, and new articles
--------------------------------------------------------------------------------

- Approved exercisability of warrants issued in October 2025 offering under Nasdaq Listing Rule 5635(d).
- Approved sub-division and re-designation of ordinary shares into 1 ordinary share (0.000000005 GBP) and 19,999 deferred shares.
- Authorised directors to allot shares up to nominal amount of USD 3,000, expiring June 30, 2030.
- Approved a share buyback contract for all deferred shares and adoption of new articles of association.
- Special resolution passed to allot equity securities for cash without pre-emption rights, effective for five years.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1541157/000149315225027969/0001493152-25-027969-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1541157/000149315225027969/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-027969

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer